Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: possible implications in cardioplegia.
Hyperkalemic solutions that are used as cardioplegic agents, while effective in inducing electromechanical arrest, are only partially cardioprotective, and ventricular dysfunction has been observed. The underlying pathophysiology of cardioplegia-associated ventricular dysfunction is complex and not fully understood, but it could be related, in part, to intracellular Ca2+ loading induced by high K+ concentrations present in cardioplegic solutions. Yet no effective cytoprotective means against possible intracellular Ca2+ loading, under these conditions, has been described. Recently, potassium channel openers, which open adenosine triphosphate-sensitive K+ channels, have been reported to possess cardioprotective properties under global ischemic conditions. However, it is not known whether these novel agents could prevent intracellular Ca2+ loading that could occur during cardioplegia. Intracellular Ca2+ was monitored in ventricular myocytes, loaded with the Ca(2+)-sensitive fluorescent probe Fluo-3AM, using epifluorescent digital imaging and laser confocal microscopy. Exposure of a myocyte to a 16 mmol/L concentration of K+, a concentration of K+ commonly used in cardioplegic solutions, induced a nonhomogeneous increase in intracellular Ca2+. Potassium channel opening drugs, such as aprikalim or nicorandil, effectively prevented these solutions from increasing intracellular Ca2+. The preventive effect of potassium channel opening drugs was antagonized by glyburide, a selective blocker of adenosine triphosphate-sensitive K+ channels. This study demonstrates, at the single cardiac cell level, that solutions containing a 16 mmol/L concentration of K+ promote intracellular Ca2+ loading, which can be prevented by potassium channel opening drugs. Therefore, potassium channel opening drugs should be considered to prevent intracellular Ca2+ loading associated with the use of cardioplegic solutions.
López
J R
JR
Department of Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Jahangir
R
R
Jahangir
A
A
Shen
W K
WK
Terzic
A
A
D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000378:metabolism; D000814:Aniline Compounds; D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002314:Cardioplegic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D002478:Cells, Cultured; D005456:Fluorescent Dyes; D005905:Glyburide / Q000494:pharmacology; D006168:Guinea Pigs; D006324:Heart Arrest, Induced; D006352:Heart Ventricles / Q000166:cytology / Q000378:metabolism; D006982:Hypertonic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D007091:Image Processing, Computer-Assisted; D015640:Ion Channel Gating / Q000187:drug effects*; D018613:Microscopy, Confocal; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D020108:Nicorandil; D010847:Picolines / Q000494:pharmacology; D011188:Potassium / Q000008:administration & dosage / Q000009:adverse effects; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000187:drug effects*; D011714:Pyrans / Q000494:pharmacology; D018754:Ventricular Dysfunction / Q000209:etiology / Q000503:physiopathology; D014966:Xanthenes
D000814:Aniline Compounds; D002121:Calcium Channel Blockers; D002314:Cardioplegic Solutions; D005456:Fluorescent Dyes; D006982:Hypertonic Solutions; D010847:Picolines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D011714:Pyrans; D014966:Xanthenes; C059715:Fluo-3; D009536:Niacinamide; D020108:Nicorandil; C061043:aprikalim; D000255:Adenosine Triphosphate; D011188:Potassium; D005905:Glyburide; D002118:Calcium